Common Contracts

27 similar null contracts by VBI Vaccines Inc/Bc, Argo Blockchain PLC, Evofem Biosciences, Inc., others

Scilex Holding Company 5,882,353 Shares of Common Stock (par value $0.0001 per share) (the “Common Stock”) 5,882,353 Warrants to Purchase 5,882,353 Shares of Common Stock Underwriting Agreement
Scilex Holding Co • March 5th, 2024 • Biological products, (no disgnostic substances) • New York

Scilex Holding Company, a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 5,882,353 shares of its common stock, par value $0.0001 per share (the “Shares”, and the 5,882,353 Shares to be sold by the Company are called the “Firm Shares”) and (ii) an aggregate of warrants to purchase an aggregate of 5,882,353 shares of Common Stock, in the form set forth in Schedule B hereto, to purchase shares of Common Stock (the “Firm Warrants”). The Firm Shares, together with the Firm Warrants, are herein called the “Firm Securities.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 882,352 shares of Common Stock (the “Optional Shares”) and/or Common Warrants to purchase up to an aggregate of 882,352 shares of Common Stock (the “Optional Warrants,” and together with the Optional Shares, the “Optional Securiti

AutoNDA by SimpleDocs
2 - Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. As used herein, “Applicable Time” is 9:00 p.m. (New York City time) on January 2, 2024. As...
Arrowhead Pharmaceuticals, Inc. • January 4th, 2024 • Pharmaceutical preparations • New York
8,461,542 Shares 769,230 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT
Xenon Pharmaceuticals Inc. • November 30th, 2023 • Pharmaceutical preparations • New York
SCILEX HOLDING COMPANY Shares of Common Stock (par value $0.0001 per share) Underwriting Agreement
Scilex Holding Co • July 13th, 2023 • Biological products, (no disgnostic substances) • New York

Scilex Holding Company, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of shares of its common stock, par value $0.0001 per share (the “Shares”). The Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional Shares. The additional Shares to be sold by the Company pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean

VBI Vaccines Inc. 10,909,091 Common Shares 10,909,091 Common Warrants to Purchase 10,909,091 Common Shares Underwriting Agreement
VBI Vaccines Inc/Bc • July 7th, 2023 • Pharmaceutical preparations • New York
8,275,000 Shares Pre-Funded Warrants to Purchase 1,250,000 Shares Travere Therapeutics, Inc. UNDERWRITING AGREEMENT
Travere Therapeutics, Inc. • March 1st, 2023 • Pharmaceutical preparations • New York
Alaunos Therapeutics, Inc. 24,228,719 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Alaunos Therapeutics, Inc. • November 30th, 2022 • Pharmaceutical preparations • New York

Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Cantor Fitzgerald & Co. (“Cantor” or the “Underwriter”) an aggregate of 24,228,719 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”). The 24,228,719 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriter an option to purchase up to an additional 3,634,307 Shares as provided in Section 2. The additional 3,634,307 Shares to be sold by the Company pursuant to such option are called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.”

Evofem Biosciences, Inc. 22,665,000 Shares of Common Stock 12,835,000 Pre- Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 71,000,000 Shares of Common Stock Underwriting Agreement
Evofem Biosciences, Inc. • May 23rd, 2022 • Pharmaceutical preparations • New York

Evofem Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 22,665,000 shares of common stock (the “Common Stock”), par value $0.0001 per share (the “Firm Shares”), and (b) 12,835,000 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,835,000 shares of Common Stock at an exercise price of $0.001 per share and (ii) 71,000,000 common stock warrants to purchase 71,000,000 shares of Common Stock (the “Common Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by the Underwriters is set forth opposite its name on Schedule A hereto. In addition, the Company has granted to the Underwriters an option to purchase no additional shares of Common Stock (the “Option Shares”) and/or no Common Warrants to purchase shares of Common Stock (the “Option Warrants

COHBAR, INC. 20,833,334 Shares of Common Stock (par value $0.001 per share) and Warrants to Purchase 20,833,334 Shares of Common Stock Underwriting Agreement
CohBar, Inc. • October 28th, 2021 • Pharmaceutical preparations • New York

CohBar, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 20,833,334 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants of the Company to purchase an aggregate of 20,833,334 shares of Common Stock (the “Warrants”). Each Share is being sold together with one Warrant; and each full Warrant is exercisable for one Common Share at an exercise price of $0.72 per whole share. The Shares and the Warrants to be sold by the Company are collectively called the “Offered Securities.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Securities. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwriter,

Argo Blockchain plc [ n ] American Depositary Shares Representing [ n ] Ordinary Shares (Nominal Value £0.001 Per Share) UNDERWRITING AGREEMENT
Argo Blockchain PLC • September 17th, 2021 • Services-computer processing & data preparation • New York
Argo Blockchain plc [ n ] American Depositary Shares Representing [ n ] Ordinary Shares (Nominal Value £0.001 Per Share) UNDERWRITING AGREEMENT
Argo Blockchain PLC • September 14th, 2021 • Services-computer processing & data preparation • New York
PORTAGE BIOTECH INC. 1,000,000 Ordinary Shares (no par value per share) Underwriting Agreement
Portage Biotech Inc. • June 24th, 2021 • Crude petroleum & natural gas • New York

Portage Biotech Inc., a British Virgin Islands company (the "Company"), proposes to issue and sell to the several underwriters named in Schedule A (the "Underwriters") an aggregate of 1,000,000 shares (the "Shares") of its ordinary shares, no par value per share (the "Ordinary Shares"). The 1,000,000 Shares to be sold by the Company are called the "Firm Shares." In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,000,000 Shares pursuant to such option are collectively called the "Option Shares." The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the "Offered Shares." Cantor Fitzgerald & Co. ("Cantor") has agreed to act as representative of the several Underwriters (in such capacity, the "Representative") in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term "Representative" as used herein

Evofem Biosciences, Inc. 50,000,000 Shares of Common Stock No Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 50,000,000 Shares of Common Stock Underwriting Agreement
Evofem Biosciences, Inc. • May 19th, 2021 • Pharmaceutical preparations • New York

Evofem Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 50,000,000 shares of common stock (the “Common Stock”), par value $0.0001 per share (the “Firm Shares”), and (b) no pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock at an exercise price of $0.01 per share and (ii) 50,000,000 common stock warrants to purchase 50,000,000 shares of Common Stock (the “Common Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by the Underwriters is set forth opposite its name on Schedule A hereto. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 7,500,000 shares of Common Stock (the “Option Shares”) and/or 7,500,000 Common Warrants to purchase up to an aggregate of 7,500,000 shares of

Edesa Biotech, Inc. 1,562,500 Common Shares (no par value per share) Amended and Restated Underwriting Agreement
Edesa Biotech, Inc. • February 26th, 2021 • Pharmaceutical preparations • New York

Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,562,500 of its common shares (the “Firm Shares”), no par value per share (the “Common Shares”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional 234,375 Common Shares as provided in ‎Section 2. The additional 234,375 Common Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“Wainwright”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters l

UR-ENERGY INC. 14,722,200 Common Shares (no par value) and Warrants to Purchase 7,361,100 Common Shares Underwriting Agreement
Ur-Energy Inc • February 4th, 2021 • Gold and silver ores • New York

Ur-Energy Inc., a corporation continued under the Canada Business Corporations Act (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 14,722,200 of its common shares (the “Firm Shares”), no par value per share (the “Common Shares”), and (ii) 14,722,200 warrants of the Company to purchase an aggregate of 7,361,100 Common Shares (the “Firm Warrants”). In addition, the Company has granted to the Underwriters an option to purchase (i) up to an additional 2,208,330 Common Shares pursuant to such option (the “Option Shares” and together with the Firm Shares, the “Shares”) and/or (ii) 2,208,330 additional warrants to purchase up to an additional 1,104,165 Common Shares (the “Option Warrants” and together with the Firm Warrants, the “Warrants”). Each Share is being sold together with one-half Warrant; and each full Warrant is exercisable for one Common Share at an exercise price of $1.35 per whole share. The Shar

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 19,430,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Pacific Biosciences of California, Inc. • August 14th, 2020 • Laboratory analytical instruments • New York

Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 19,430,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 19,430,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,914,500 Shares. Such additional 2,914,500 Shares to be sold by the Company, if any, pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” Morgan Stanley & Co. LLC (“Morgan Stanley”) and Cowen and Company, LLC (“Cowen”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To

EX-1.1 2 d485869dex11.htm EX-1.1 Taiwan Liposome Company, Ltd. [•] American Depositary Shares (par value NT$10 per share) Underwriting Agreement [DATE] Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto...
New York • May 5th, 2020

Taiwan Liposome Company, Ltd., a Taiwanese stock corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [•] American Depositary Shares (“ADSs”), representing two shares of common stock (the “Common Stock”), nominal value NT$10 per share (the “Firm Securities”) pursuant to this underwriting agreement (the “Agreement”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional [•] ADSs representing [•] shares of Common Stock pursuant to such option, which are collectively called the “Option Securities.” The Firm Securities and, if and to the extent such option is exercised, the Option Securities, are collectively called the “Offered Securities.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Securities. To the extent

VBI Vaccines Inc. 45,454,545 Common Shares (no par value per share) Underwriting Agreement
VBI Vaccines Inc/Bc • April 24th, 2020 • Pharmaceutical preparations • New York

VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 45,454,545 common shares, no par value per share (the “Shares”). The 45,454,545 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 6,818,181 Shares as provided in ‎Section 2. The additional 6,818,181 Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” Raymond James & Associates, Inc. (“Raymond James”) and Oppenheimer and Co. Inc. (“Oppenheimer”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection

par value $0.001 per share) Underwriting Agreement
Opiant Pharmaceuticals, Inc. • September 27th, 2018 • Metal mining • New York

Opiant Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 705,882 shares of its common stock, par value $0.001 per share (the “Shares”). The 705,882 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 105,882 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwri

Taiwan Liposome Company, Ltd. [•] American Depositary Shares (par value NT$10 per share) Underwriting Agreement
Taiwan Liposome Company, Ltd. • April 16th, 2018 • Pharmaceutical preparations • New York

Taiwan Liposome Company, Ltd., a Taiwanese stock corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [•] American Depositary Shares (“ADSs”), representing two shares of common stock (the “Common Stock”), nominal value NT$10 per share (the “Firm Securities”) pursuant to this underwriting agreement (the “Agreement”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional [•] ADSs representing [•] shares of Common Stock pursuant to such option, which are collectively called the “Option Securities.” The Firm Securities and, if and to the extent such option is exercised, the Option Securities, are collectively called the “Offered Securities.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Securities. To the extent

Affimed N.V. 11,500,000 Common Shares (Par Value €0.01 Per Share) UNDERWRITING AGREEMENT
Affimed N.V. • February 15th, 2018 • Pharmaceutical preparations • New York
Sol-Gel Technologies Ltd. [●] Ordinary Shares (Par Value NIS 0.1 Per Share) UNDERWRITING AGREEMENT
Sol-Gel Technologies Ltd. • January 23rd, 2018 • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
VBI Vaccines Inc. 14,000,000 Common Shares (no par value per share) Underwriting Agreement
VBI Vaccines Inc/Bc • October 27th, 2017 • Pharmaceutical preparations • New York

VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 14,000,000 common shares, no par value per share (the “Shares”). The 14,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,100,000 Shares as provided in ‎Section 2. The additional 2,100,000 Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” BMO Capital Markets Corp. (“BMOCM”) and Canaccord Genuity Inc. (“Canaccord”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering a

uniQure N.V. 5,000,000 Ordinary Shares (Nominal Value € 0.05 Per Share) UNDERWRITING AGREEMENT
uniQure N.V. • October 26th, 2017 • Pharmaceutical preparations • New York

uniQure N.V., a Dutch public company with limited liability (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,000,000 ordinary shares, nominal value €0.05 per share (the “Ordinary Shares”). The 5,000,000 Ordinary Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 750,000 Ordinary Shares as provided in Section 2. The additional 750,000 Ordinary Shares to be sold pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Leerink Partners LLC (“Leerink”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters

5,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 775,000 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT
Savara Inc • October 25th, 2017 • Pharmaceutical preparations • New York
NeuroDerm Ltd. 4,000,000 Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT
NeuroDerm Ltd. • December 8th, 2016 • Pharmaceutical preparations • New York
NeuroDerm Ltd. [ ] Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT
NeuroDerm Ltd. • July 13th, 2015 • Pharmaceutical preparations • New York
Time is Money Join Law Insider Premium to draft better contracts faster.